Table 1 Demographics and treatment history of 236 chronic-phase CML patients who discontinued TKI treatment in DMR in Spain from April 2009 to February 2018

Age at TKI discontinuation, year^a

61 (52–72)

Sex, females (%)

123 (52)

Sokal risk score, n (%)

 Low

129 (60)

 Intermediate

69 (32)

 High

17 (8)

 Unknown

21

Time from diagnosis to TKI discontinuation, months^a

130 (96–162)

Prior interferon treatment, n (%)

55 (23)

TKI lines before TKI discontinuation, n (%)

 One

184 (78)

 Two

32 (14)

 Three

20 (8)

TKI at the time of treatment cessation, n (%)

 Imatinib

175 (74)

 Nilotinib

41 (17.5)

 Dasatinib

17 (7)

 Bosutinib

1 (0.5)

 Ponatinib

2 (1)

History of resistance to any TKI, n (%)

17 (7)

Duration of TKI treatment, months^a

123.5 (93–150)

Time in MR4.5 before TKI discontinuation, months^a

68 (40–100)